Health
Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds – News-Medical.Net – Burnie Online News
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
Continue Reading
-
General23 hours agoDeath of 86-year-old driver in Karoonda Highway crash prompts push for change
-
General19 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
Business18 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
Noosa News22 hours agoStory Bridge documents released amid cover-up claims